Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more
than 28%. The TACE treatment, under the theoretical basis of blood supply of Liver cancer,
is obviously better than the other non-surgical therapy, in terms of tumor regression, AFP
decrease, survival time and the evaluation of the quality of life. Licartin injection is a
antibody drug with new target and the only drug that China own the intellectual property
rights. It has specific high affinity with HAb18G/CD147, the liver cell membrane antigen.
Labeled 131I is taken to the liver tissue, owning high-dose concentration and releasing β
particles to liver cancer cells to and kill cancer cells.
The Second Military Medical University, Eastern Hepatobiliary Surgery Hospital, planed to
use the treatment of Licartin combined with TACE for the patients of unresectable
hepatocellular carcinoma and evaluate the difference of tumor size, AFP change, TTP, the
overall survival rate between different treatment group.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
OS of 1 years; TTP
Yang yefa, doctor
The Second Military Medical University
China: Food and Drug Administration